TACTIC Press and Publications

Drug Development: German Cancer Aid Funds Two Projects at Goethe

The German Cancer Aid is now supporting two cancer research projects with around €16 million, in which promising drug candidates undergo preclinical testing to prepare for clinical approval studies. The University Hospitals of Frankfurt and Würzburg are leading the “CAR Factory” project, which focuses on using genetically engineered immune cells to fight tumors. In the TACTIC project, coordinated by Goethe University, small molecules are being developed to help reset disrupted genetic switches in cancer cells.

Cancer Research with TACTIC: Searching for the Right Switches

With €11.8 million in funding until 2028, the German Cancer Aid (DKH) is supporting a promising joint project in which researchers from the Faculty of Medicine at the University of Duisburg-Essen (UDE) play a key role.TACTIC aims to more precisely target the genetic causes of cancer with innovative drugs.Led by Prof. Dr. Christian Reinhardt (UDE), Prof. Dr. Stefan Knapp (Goethe University Frankfurt), and Prof. Dr. Daniel Rauh (TU Dortmund), the project brings together experts in chemical biology, drug discovery, and oncology. A national oncology drug research center is being established to support the project’s goals

“TACTIC”: Developing Cancer Drugs at Universities

Frankfurt am Main – Our genes serve as blueprints for proteins, each performing specific functions in our cells. These processes are controlled by transcription factors. In cancer cells, this regulation is often disrupted. Many transcription factors have now been linked to cancer development.Through its new funding program for “Preclinical Drug Development”, the German Cancer Aid is supporting the large-scale TACTIC project.This nationwide research network is developing drugs that interact directly with dysregulated transcription factors in tumors, aiming to restore cancer cells to their normal state.

TACTIC Against Cancer – German Cancer Aid Supports Research Netw

The German Cancer Aid is funding the TACTIC research network for five years with a total of €11.8 million.The goal: discovery and advancement of novel therapeutic compounds up to preclinical trials. Research institutions such as IfADo are also part of this nationwide effort.

€20 Million for the Development of New Cancer Therapies

From the lab to the patient’s bedside – before a new cancer drug can be used in treatment, it must undergo a series of preclinical tests to ensure safety and effectiveness.Because these studies are time- and cost-intensive, research into drugs for rare or hard-to-treat cancers is often not commercially attractive for pharmaceutical companies. The German Cancer Aid aims to close this gap. At the 36th German Cancer Congress 2024, it is presenting its new focus program “Preclinical Drug Development”, through which three major projects – including TACTIC – will receive a total of €20 million over five years.

TACTIC – Oncogenic Transcription as a Target for New Cancer Ther

Cancer arises from genetic and epigenetic changes, which lead to dysregulated transcription programs. Key elements include gene expression control mechanisms, the basic transcription machinery, and mRNA processing – all offering a range of therapeutic targets. Another promising avenue: targeting tumor-specific transcription mechanisms.  However, most oncogenic transcription factors are difficult to inhibit directly with small molecules. TACTIC aims to change that through innovative, tailored drug development strategies.

Publications

  1. Werr L, Boland J, Petersen J, Iglesias F, Höppner S, Bartenhagen C, Rosswog C, Hellmann AM, Kahlert Y, Hemstedt N, Ibruli N, Dammert MA, Decarolis B, Werner JM, Malchers F, Schramm K, Witt O, Beiske KH, Rognlien AGW, Gunnes MW, Langenberg KP, Molenaar J, Bernkopf M, Taschner-Mandl S, Hughes D, George SL, Chesler L, Schulte JH, Barone G, Capasso M, Surrey LF, Bagatell R, Masliah-Planchon J, Schleiermacher G, Grüll H, Westermann F, Schultheis AM, Büttner R, Henssen AG, Eggert A, Peifer M, Shukla NN, Simon T, Hero B, Reinhardt HC, Thomas RK, Fischer M. J Clin Invest.Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma. 2026 Feb 12;136(7):e189152. doi: 10.1172/JCI189152. eCollection 2026 Apr 1. PubMed

  2. Mueller S, de Andrade Krätzig N, Tschurtschenthaler M, Silva MG, Thordsen C, Trozzo R, Simon P, Saab F, Kaltenbacher T, Zukowska M, Lucarelli D, Öllinger R, Griger J, Groß N, Groll T, Löprich J, Zaurito AE, Schömig LR, Bugter JM, Bärthel S, Falcomatà C, Strong A, Brandt C, Najajreh M, Papargyriou A, Maresch R, Collins KAN, Sailer D, Schneeweis C, Burger S, Fröhlich LM, Klement C, Belka A, Montero JJ, Jungwirth U, Reichert M, Moser M, Neumann J, Vassiliou G, Cadiñanos J, Varela I, Marr C, Alonso DF, Lollini PL, Zhao J, Chesler L, Isacke CM, Riedel A, Braun CJ, Sos ML, Beleggia F, Reinhardt HC, Musteanu M, Barbacid M, Quante M, Schmidt-Supprian M, Schneider G, Clare S, Lawley TD, Dougan G, Steiger K, Conte N, Bradley A, Rad L, Saur D, Rad R. A disease model resource reveals core principles of tissue-specific cancer evolution.

    Nature. 2026 Feb 25. doi: 10.1038/s41586-026-10187-2. Online ahead of print. PubMed

  3. Zhang R, Huetzen MA, Binici A, Martín-Gago P, Gasper R, Rudashevskaya E, Liu J, Nagaraju C, Reckzeh ES, Stuedle AST, Hopff AS, Mesaros A, Unger A, Thelen M, Janning P, Reinhardt HC, Ziegler S, Jachimowicz RD, Waldmann H.Targeting a Glutamic Acid in PDEδ with Fluoromethyl-Aryl Electrophiles Impairs K-Ras Signaling.  J Med Chem. 2026 Jan 22;69(2):964-981. doi: 10.1021/acs.jmedchem.5c02082. Epub 2026 Jan 7.  PubMed

  4. O'Hanlon JA, Gutsche K, Muller JE, Ranjan Prusty N, Mirza A, Roumeliotis TI, Yang H, Stubbs M, Hallett ST, Eing L, McAndrew PC, Choudhary JS, Le Bihan YV, Caldwell J, van Montfort RLM, Workman P, Wolf E, Newton GK, and Evans LE (2026). Unhooking the Hook: Optimization of the Aurora A Targeting PROTAC JB170 to CCT400028, an In Vitro Degrader Chemical Probe. J Med Chem 69: 1552-1567. PubMed

  5. Berner N et al, Proteome-wide dose-response measurements for the characterization of drug mechanism of action, Targetome, 2026, doi:10.48130/ targetome-0025-0011

  6. Scholes NS, Bertoni M, Comajuncosa-Creus A, Kladnik K, Guo X, Frommelt F, Hinterndorfer M, Razumkov H, Prokofeva P, Schwalm MP, Born F, Roehm S, Imrichova H, Santini BL, Barone E, Schatz C, Munoz IOM, Lechner S, Rukavina A, Serrano I, Abele M, Koren A, Kubicek S, Knapp S, Gray NS, Superti-Furga G, Kuster B, Shi Y, Aloy P, and Winter GE (2026). Inhibitors supercharge kinase turnover through native proteolytic circuits. Nature 649: 1032-1041. PubMed

  7. Zhang R, Huetzen MA, Binici A, Martin-Gago P, Gasper R, Rudashevskaya E, Liu J, Nagaraju C, Reckzeh ES, Stuedle AST, Hopff AS, Mesaros A, Unger A, Thelen M, Janning P, Reinhardt HC, Ziegler S, Jachimowicz RD, and Waldmann H (2026). Targeting a Glutamic Acid in PDEdelta with Fluoromethyl-Aryl Electrophiles Impairs K-Ras Signaling. J Med Chem 69: 964-981. PubMed

  8. Mitrovic M, Greco FA, Garcia YC, Lucic A, Hoffmann L, Chander R, Schonfeld J, Liebisch N, Sivashanmugam SA, Schwalm MP, Egner M, Lewandowski M, Merk D, Morasch V, Wolf E, Muller S, Hanke T, Proschak E, Hiesinger K, and Knapp S (2026). Click. Screen. Degrade. A Miniaturized D2B Workflow for Rapid PROTAC Discovery. J Med Chem. PubMed

  9. Meder L, Orschel CI, Bouchez CL, Gholamipoorfard R, Orschel CV, Stahl D, Kreer C, Koker M, Nill M, Kocak IG, Noh KW, Zhao X, Ullrich L, Häupl B, Jakob J, Eich ML, Florin A, Grüll H, Wolf J, Beleggia F, Büttner R, Oellerich T, Klein F, Brägelmann J, Reinhardt HC, Abedpour N, Ullrich RT. Nat ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer. Commun. 2025 Dec 9;16(1):10983. doi: 10.1038/s41467-025-66800-x. PubMed

  10. Wolf E, Newton GK, and Evans LE (2026). Unhooking the Hook: Optimization of the Aurora A Targeting PROTAC JB170 to CCT400028, an In Vitro Degrader Chemical Probe. J Med Chem 69: 1552-1567. PubMed

  11. Wang X, Sun J, Ahmad S, Yang D, Li F, Chan UH, Zeng H, Simoben CV, Green SR, Silva M, Houliston S, Dong A, Bolotokova A, Gibson E, Kutera M, Ghiabi P, Kondratov I, Matviyuk T, Chuprina A, Mavridi D, Lenz C, Joerger AC, Brown BD, Heath RB, Yue WW, Robbie LK, Beyett TS, Muller S, Knapp S, Owen DR, Harding R, Schapira M, Brown PJ, Santhakumar V, Ackloo S, Arrowsmith CH, Edwards AM, Peng H, and Halabelian L (2025). Enantioselective protein affinity selection mass spectrometry (E-ASMS). Nat Commun 17: 651. Pubmed

  12. Sakthivelu V, Schmitt A, Odenthal F, Ndoci K, Touet M, Shaib AH, Chihab A, Wani GA, Nieper P, Hartmann GG, Pintelon I, Kisis I, Boecker M, Eckert NM, Iannicelli Caiaffa M, Ibruli O, Weber J, Maresch R, Bebber CM, Chitsaz A, Lütz A, Kim Alves Carpinteiro M, Morris KM, Franchino CA, Benz J, Pérez-Revuelta L, Soriano-Campos JA, Huetzen MA, Goergens J, Jevtic M, Jahn-Kelleter HM, Zempel H, Placzek A, Hennrich AA, Conzelmann KK, Tumbrink HL, Hunold P, Isensee J, Werr L, Gaedke F, Schauss A, Minère M, Müller M, Fenselau H, Liu Y, Heimsoeth A, Gülcüler Balta GS, Walczak H, Frezza C, Jachimowicz RD, George J, Schmiel M, Brägelmann J, Hucho T, von Karstedt S, Peifer M, Annibaldi A, Hänsel-Hertsch R, Persigehl T, Grüll H, Sos ML, Reifenberger G, Fischer M, Adriaensen D, Büttner R, Sage J, Brouns I, Rad R, Thomas RK, Anstötz M, Rizzoli SO, Bergami M, Motori E, Reinhardt HC, Beleggia F. Functional synapses between neurons and small cell lung cancer.Nature. 2025 Oct;646(8087):1243-1253. doi: 10.1038/s41586-025-09434-9. Epub 2025 Sep 10. PubMed

  13. Androulidaki A, Liu F, Bebber CM, Kisis I, Sakthivelu V, Hunold P, Koerner L, Dahlhaus A, Yapici FI, Grimm C, Pacholewska A, Tishina S, Doskotz F, Torres Fernandez LA, Stroh J, Abdallah AT, Beck J, Mulalic L, Schmitt A, Grull H, Persigehl T, Quaas A, Peifer M, Bragelmann J, Reinhardt HC, Nieper P, Hansel-Hertsch R, Thomas RK, George J, Schweiger MR, Pasparakis M, Beleggia F, and von Karstedt S (2025). Lack of caspase 8 directs neuronal progenitor-like reprogramming and small cell lung cancer progression. Nat Commun 16: 11280. PubMed

  14. Dampmann M, von Tresckow B, Reinhardt HC, Kuppers R, and von Tresckow J (2025). Insights into the pathogenesis and biology of chronic lymphocytic leukemia through analysis of its B-cell receptor. Leuk Lymphoma 66: 1778-1787.PubMed

  15. Castelli S, Wilson WV, Uslu U, Finck AV, Rommel PC, Assenmacher CA, Atoche SJ, Siurala M, Aznar MA, Young RM, and June CH (2026). IL-9 signaling redirects CAR T cell fate toward CD8(+) memory and CD4(+) cycling states, enhancing antitumor efficacy. Immunity 59: 195-212 e11. PubMed

  16. Hesterberg RS, Davis JT, Handoo KJ, Elmarsafawi AG, Augello AC, Cheng CH, Atkins R, Lee DH, Yang C, Yao J, Patel KR, Mediavilla-Varela M, Pinilla-Ibarz J, Soto-Palma C, Locke FL, Song X, Wang X, Berglund AE, Rodriguez PC, Knittel G, Flumann R, Reinhardt HC, Shaw TI, Yu X, Niedernhofer LJ, and Cleveland JL (2025). Lymphoma accelerates T cell and tissue aging. Cancer Cell 43: 1917-1936 e8. PubMed

  17. Stahl D, Gödel P, Balke-Want H, Gholamipoorfard R, Segbers P, Tetenborg L, Koker M, Dörr J, Gregor L, Bachurski D, Rose F, Simon AG, Good Z, Jakob J, Häupl B, Nill M, Flümann R, Riet T, Lange D, Blakemore SJ, Baurmann H, Voltin CA, Potter N, Schlözer L, Freihammer M, Wagener-Ryczek S, Iuga AI, Heger JM, Ludwig H, Schleifenbaum JK, Propp J, Bröckelmann PJ, Jachimowicz RD, Knittel G, Borchmann S, Merkelbach-Bruse S, Pallasch C, Peifer M, Rybniker J, Quaas A, Nitz M, Brägelmann J, Müller W, Persigehl T, Bozek K, Theobald SJ, Büttner R, Oellerich T, Hallek M, Kobold S, Chmielewski M, Reinhardt HC, Mackall C, Abedpour N, Borchmann P, Ullrich RT.CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma. Cancer Cell. 2025 Aug 11;43(8):1476-1494.e10. doi: 10.1016/j.ccell.2025.05.013. Epub 2025 Jun 12. PubMed

  18. Kirschner T, Rodriguez J, Moreira EG, Niggenaber J, Warmuth JD, Verli H, Muller MP, and Rauh D (2025). Targeting KRAS(G13C) with cyclic linker based inhibitors to explore warhead orientation. Sci Rep 15: 38213.PubMed

  19. Hoffmann L, Lenz C, Farges F, Kimani SW, Dopfer J, Keller S, Schwalm MP, Holzmann H, Kraemer A, Dong A, Li F, Chau I, Halabelian L, Gstaiger M, Muller S, Knapp S, and Nemec V (2025). Discovery of an exquisitely selective WDR5 chemical probe accelerated by a high-quality DEL-ML Hit. RSC Chem Biol 6: 1585-1594. PubMed

  20. Wang G, Seidler NJ, Rohm S, Pan Y, Liang XJ, Haarer L, Berger BT, Sivashanmugam SA, Wydra VR, Forster M, Laufer SA, Chaikuad A, Gehringer M, and Knapp S (2025). Probing the Protein Kinases' Cysteinome by Covalent Fragments. Angew Chem Int Ed Engl 64: e202419736. PubMed

  21. Hunold P, Pizzolato G, Heramvand N, Kaiser L, Barbiera G, van Ray O, Thomas R, George J, Peifer M, and Hansel-Hertsch R (2025). DynaTag for efficient mapping of transcription factors in low-input samples and at single-cell resolution. Nat Commun 16: 6585. Pubmed

  22. Falkenhorst J, Ivanyi P, Schulz T, Hamacher R, Kasper B, Hohenberger P, Deinzer CKW, Pink D, Fletcher BS, Haller V, Optaczy Y, Grunewald S, Rauh D, Marino-Enriquez A, Muhlenberg T, Reichardt P, and Bauer S (2025). Phase 2 trial of ponatinib in patients with metastatic gastrointestinal stromal tumor following failure or intolerance of prior therapy with imatinib (POETIG trial). Clin Cancer Res. PubMed

  23. Hillebrand L, Wang G, Rasch A, Masberg B, Chaikuad A, Kronenberger T, Gunther E, Forster M, Poso A, Lammerhofer M, Laufer SA, Knapp S, and Gehringer M (2025). A twist in the tale: shifting from covalent targeting of a tyrosine in JAK3 to a lysine in MK2. RSC Med Chem.PubMed

  24. Zhubi R, Chaikuad A, Munoz Sosa CJ, Joerger AC, and Knapp S (2025). Structural analysis of TRIM family PRYSPRY domains and its implications for E3-ligand design. J Struct Biol X 12: 100134. PubMed

  25. Schonfeld J, Brunst S, Ciomirtan L, Willmer L, Chromik MA, Kumar A, Froemel T, Liebisch N, Hackspacher A, Ehrler JHM, Wintermeier L, Hesse C, Fiedler J, Heering J, Freitag H, Zardo P, Fieguth HG, Bruggerhoff A, Jakob J, Haupl B, Weizel L, Kaiser A, Schubert-Zsilavecz M, Oellerich T, Fleming I, Schebb NH, Furst R, Kannt A, Knapp S, Proschak E, and Hiesinger K (2025). Structure-Based Design of PROTACS for the Degradation of Soluble Epoxide Hydrolase. J Med Chem 68: 13728-13749. PubMed

  26. Mandel S, Hanke T, Prendiville N, Baena-Nuevo M, Berger LM, Farges F, Schwalm MP, Berger BT, Kraemer A, Elson L, Saraswati H, Abdul Azeez KR, Dederer V, Mathea S, Corrionero A, Alfonso P, Keller S, Gstaiger M, Krause DS, Muller S, Rohm S, and Knapp S (2025). Covalent Targeting Leads to the Development of a LIMK1 Isoform-Selective Inhibitor. J Med Chem 68: 15026-15049. PubMed

  27. Munick P, Strubel A, Balourdas DI, Funk JS, Mernberger M, Osterburg C, Dreier B, Schaefer JV, Tuppi M, Yuksel B, Schafer B, Knapp S, Pluckthun A, Stiewe T, Joerger AC, and Dotsch V (2025). DARPin-induced reactivation of p53 in HPV-positive cells. Nat Struct Mol Biol 32: 790-801.PubMed

  28. Serafim RAM and Gehringer M (2025). High-Quality In Vivo Chemical Probes for Protein Kinases Disclosed in 2024. ACS Pharmacol Transl Sci 8: 2401-2414.b. PubMed

  29. Tivon B, Wiese J, Muller MP, Gabizon R, Rauh D, and London N (2025). Computational Design of Lysine Targeting Covalent Binders Using Rosetta. J Chem Inf Model. PubMed

  30. Galvez BPJ, Woelffing P, Schwarz M, Ebner S, Rudalska R, Masberg B, Esposito A, Rashidian A, Schevchenko E, Smutna L, Pavek P, Kublbeck J, Kronenberger T, Zender L, Lammerhofer M, Dauch D, and Laufer SA (2025). Uncovering alpha-Selectivity for Liver X Receptor Agonists for Lipotoxic Cancer Therapies. J Med Chem 68: 7180-7196. PubMed

  31. Edmonds AK, Balourdas DI, Marsh GP, Felix R, Brasher B, Cooper J, Graber-Feesl C, Kollareddy M, Malik K, Stewart H, Chevassut TJT, Lineham E, Morley S, Fedorov O, Bennett J, Rajasekaran MB, Ojeda S, Harrison DA, Ott CJ, Joerger AC, Maple HJ, and Spencer J (2025). Structure-Guided Design of ISOX-DUAL-Based Degraders Targeting BRD4 and CBP/EP300: A Case of Degrader Collapse. J Med Chem 68: 9638-9660.PubMed

  32. Wagner K, Keiten-Schmitz J, Adhikari B, Patra U, Husnjak K, McNicoll F, Dormann D, Muller-McNicoll M, Tascher G, Wolf E, and Muller S (2025). Induced proximity to PML protects TDP-43 from aggregation via SUMO-ubiquitin networks. Nat Chem Biol. PubMed

  33. Zhao B, Fang R, Schurmann H, Hemmer EJ, Mayer GL, Trajkovic-Arsic M, Althoff K, Yang J, Godfrey L, Liffers ST, Savvatakis K, Dorsch M, Gruner BM, Hahn S, Remke M, Lueong SS, and Siveke JT (2025). PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma. Cell Rep 44: 115541. PubMed

  34. Maciel EVS, Eisert J, Dederer V, Berwanger A, Knapp S, Empting M, Mathea S, Jensen H, and Lermyte F (2025). Native Flow-Induced Dispersion Analysis - Mass Spectrometry Enables Automated, Multiplexed Ligand Screening from Conventional, Nonvolatile Buffers. Anal Chem. PubMed

  35. Muller S, Sanfelice D, and Workman P (2025). Probing cancer with small-molecule tools-Progress and challenges. Cancer Cell 43: 323-327. PubMed

  36. Willems S, Maksumic L, Niggenaber J, Lin TC, Schulz T, Weisner J, Sievers S, Muller MP, Summerer D, and Rauh D (2025). Advancing TET Inhibitor Development: From Structural Insights to Biological Evaluation. ACS Med Chem Lett 16: 804-810. PubMed

  37. Eisert J, Maciel EVS, Dederer V, Berwanger A, Bailey HJ, Dikic I, Knapp S, Empting M, Mathea S, Jensen H, and Lermyte F (2025). Native Taylor/Non-Taylor Dispersion-Mass Spectrometry (TNT-MS) Allows Rapid Protein Desalting and Multiplexed, Label-Free Ligand Screening. Small Methods: e2500658. PubMed

  38. Mandel S, Hanke T, Mathea S, Chatterjee D, Saraswati H, Berger BT, Schwalm MP, Yamamoto S, Tawada M, Takagi T, Ahmed M, Rohm S, Corrionero A, Alfonso P, Baena M, Elson L, Menge A, Kramer A, Pereira R, Muller S, Krause DS, and Knapp S (2025). Repurposing of the RIPK1-Selective Benzo[1,4]oxazepin-4-one Scaffold for the Development of a Type III LIMK1/2 Inhibitor. ACS Chem Biol. PubMed

  39. Wang X, Sun J, Ahmad S, Yang D, Li F, Chan UH, Zeng H, Simoben CV, Houliston S, Dong A, Bolotokova A, Gibson E, Kutera M, Ghiabi P, Kondratov I, Matviyuk T, Chuprina A, Mavridi D, Lenz C, Joerger AC, Brown BD, Heath RB, Yue WW, Robbie LK, Beyett TS, Muller S, Knapp S, Harding R, Schapira M, Brown PJ, Santhakumar V, Ackloo S, Arrowsmith CH, Edwards AM, Peng H, and Halabelian L (2025). Enantioselective Protein Affinity Selection Mass Spectrometry (EAS-MS). bioRxiv. PUbMed

  40. Funk JS, Klimovich M, Drangenstein D, Pielhoop O, Hunold P, Borowek A, Noeparast M, Pavlakis E, Neumann M, Balourdas DI, Kochhan K, Merle N, Bullwinkel I, Wanzel M, Elmshauser S, Teply-Szymanski J, Nist A, Procida T, Bartkuhn M, Humpert K, Mernberger M, Savai R, Soussi T, Joerger AC, and Stiewe T (2025). Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations. Nat Genet 57: 140-153. PubMed

  41. Bhandare P, Narain A, Hofstetter J, Rummel T, Wenzel J, Schulein-Volk C, Lamer S, Eilers U, Schlosser A, Eilers M, Erhard F, and Wolf E (2025). Phenotypic screens identify SCAF1 as critical activator of RNAPII elongation and global transcription. Nucleic Acids Res 53. PubMed

  42. Schulz T, Gontla R, Teuber A, Beerbaum M, Fletcher BS, Muhlenberg T, Kaitsiotou H, Hardick J, Jeyakumar K, Keul M, Muller MP, Sievers S, Bauer S, and Rauh D (2025). Design, Synthesis, and SAR of Covalent KIT and PDGFRA Inhibitors horizontal line Exploring Their Potential in Targeting GIST. J Med Chem 68: 3238-3259. PubMed

  43. Moyano PM, Kubina T, Paruch SO, Jaroskova A, Novotny J, Skockova V, Ovesna P, Suchankova T, Prokofeva P, Kuster B, Smida M, Chaikuad A, Kramer A, Knapp S, Soucek K, and Paruch K (2025). Thieno[3,2-b]pyridine: Attractive scaffold for highly selective inhibitors of underexplored protein kinases with variable binding mode. Angew Chem Int Ed Engl 64: e202412786. PubMed

  44. Miletic N, Weckesser J, Mosler T, Rathore R, Hoffmann ME, Gehrtz P, Schlesiger S, Hartung IV, Berner N, Wilhelm S, Muller J, Adhikari B, Nemec V, Sivashanmugam SA, Elson L, Holzmann H, Schwalm MP, Hoffmann L, Abdul Azeez KR, Muller S, Kuster B, Wolf E, Dikic I, and Knapp S (2025). Workflow for E3 Ligase Ligand Validation for PROTAC Development. ACS Chem Biol 20: 507-521. PubMed

  45. Haag A, Nemec V, Janovska P, Bartosikova J, Adhikari B, Muller J, Schwalm MP, Cada S, Ohmayer U, Daub H, Kim Y, Born F, Wolf E, Bryja V, and Knapp S (2025). Development and Discovery of a Selective Degrader of Casein Kinases 1 delta/epsilon. J Med Chem 68: 506-530. PubMed

  46. Pieper NM, Schnell J, Bruecher D, Knapp S, and Vogler M (2024). Inhibition of bromodomain and extra-terminal proteins targets constitutively active NFkappaB and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC. Cell Commun Signal 22: 415. PubMed

  47. Kameri E, Jepsen VH, Stachura P, Ruchel N, Bhave R, Benitez L, Crispi F, Gratacos E, Dragano N, Janssen S, Borkhardt A, Pandyra A, Kogler G, and Fischer U (2024). A gut instinct for childhood leukemia prevention: microbiome-targeting recommendations aimed at parents and caregivers. Front Public Health 12: 1445113. PubMed

  48. Zhu WF, Franz HM, Kramer A, Duman E, Empel C, Gobel MW, Koenigs RM, Knapp S, Hiesinger K, Proschak E, and Hernandez-Olmos V (2024). Oxadiazolone-Based Aromatic Annulations: A Nitrenoid Precursor for Tricyclic Aminoheterocycles. J Org Chem 89: 15542-15552. PubMed

  49. Vogt M, Dudvarski Stankovic N, Cruz Garcia Y, Hofstetter J, Schneider K, Kuybu F, Hauck T, Adhikari B, Hamann A, Rocca Y, Grysczyk L, Martin B, Gebhardt-Wolf A, Wiegering A, Diefenbacher M, Gasteiger G, Knapp S, Saur D, Eilers M, Rosenfeldt M, Erhard F, Vos SM, and Wolf E (2024). Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2. Gut 73: 1509-1528. PubMed

  50. Kramer A and Knapp S (2024). Elimination of mutant SWI/SNF complexes by protein quality control: new opportunities targeting aggressive rhabdoid tumours. Signal Transduct Target Ther 9: 224. PubMed

  51. Dobersalske C, Rauschenbach L, Hua Y, Berliner C, Steinbach A, Grüneboom A, Kokkaliaris KD, Heiland DH, Berger P, Langer S, Tan CL, Stenzel M, Landolsi S, Weber F, Darkwah Oppong M, Werner RA, Gull H, Schröder T, Linsenmann T, Buck AK, Gunzer M, Stuschke M, Keyvani K, Forsting M, Glas M, Kipnis J, Steindler DA, Reinhardt HC, Green EW, Platten M, Tasdogan A, Herrmann K, Rambow F, Cima I, Sure U, Scheffler Cranioencephalic functional lymphoid units in glioblastoma. B. Nat Med. 2024 Oct;30(10):2947-2956. doi: 10.1038/s41591-024-03152-x. Epub 2024 Jul 31. PubMed

  52. Sflakidou E, Adhikari B, Siokatas C, Wolf E, and Sarli V (2024). Development of 2-Aminoadenine-Based Proteolysis-Targeting Chimeras (PROTACs) as Novel Potent Degraders of Monopolar Spindle 1 and Aurora Kinases. ACS Pharmacol Transl Sci 7: 3488-3501. PubMed